Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-025914
Filing Date
2025-02-24
Accepted
2025-02-24 19:04:25
Documents
1
Period of Report
2025-02-21

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3615
  Complete submission text file 0000950170-25-025914.txt   5118
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Issuer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVENUE, SUITE 300E WASHINGTON DC 20037
Business Address
Moran Kevin Patrick (Reporting) CIK: 0001806596 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34186 | Film No.: 25658735